Global Pertussis Vaccine Supply, Demand and Key Producers, 2026-2032
Description
The global Pertussis Vaccine market size is expected to reach $ 7744 million by 2032, rising at a market growth of 3.4% CAGR during the forecast period (2026-2032).
In 2024, global Pertussis Vaccine production reached approximately 350 million doses, with an average global market price of around US$ 16 per square meter. Pertussis vaccine is a vaccine that protects against whooping cough. There are two main types: whole-cell vaccines and acellular vaccines. The whole-cell vaccine is about 78% effective while the acellular vaccine is 71–85% effective. In this report, we cover all the pertussis-containing vaccines. Gross margin for the Pertussis vaccine in general shows that manufacturers often achieve roughly 50–70% gross margins, depending on the producer, country, and contract.
The global pertussis vaccine market continues to grow steadily, driven by rising awareness of whooping cough, expanding childhood immunization programs, and increasing recommendations for adolescent and adult Tdap boosters. Demand is especially strong in developing regions where pertussis remains endemic, while mature markets are supported by routine pregnancy immunization and periodic booster campaigns. Major manufacturers focus on improving vaccine safety, supply stability, and combination formulations such as DTaP, which simplify national immunization schedules. Although pricing and procurement are heavily influenced by government tenders and international organizations, overall market growth is supported by public-health initiatives, technological advances in acellular vaccine production, and efforts to increase global vaccination coverage. The pertussis vaccine industrial chain is a complex, highly regulated, and technology-intensive ecosystem that spans from upstream antigen research to downstream global immunization delivery. It is characterized by significant barriers to entry, stringent quality control, and a delicate balance between public health objectives and commercial viability. The chain begins with basic and applied research into Bordetella pertussis antigens. This includes the identification, genetic sequencing, and optimization of key immunogenic components such as Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA), Pertactin (PRN), and Fimbrial proteins (FIM). For acellular vaccines (aP), the upstream segment involves mastering large-scale fermentation, toxin purification, and detoxification (converting PT to Toxoid) processes. This stage also encompasses the production of specialized adjuvants (e.g., aluminum salts) and critical raw materials for cell culture media and buffers. Innovation here focuses on improving antigen yield, purity, stability, and developing novel adjuvant systems to enhance and prolong immunity. The demand for pertussis vaccines is driven by the persistent prevalence of whooping cough, growing awareness of immunization benefits, and expanding vaccination programs for infants, adolescents, and adults. Rising adoption of Tdap boosters during pregnancy and among healthcare workers further fuels market growth. Opportunities exist in developing countries where vaccination coverage is still limited, as well as in urban areas of developed nations with increasing focus on adult immunization and combination vaccines like DTaP to simplify schedules. Additionally, technological innovations in acellular vaccine production, improvements in cold-chain logistics, and government-supported public health initiatives create potential for new market entrants and partnerships. Manufacturers that can offer safe, effective, and easily deployable vaccines, along with reliable supply chains, are well-positioned to capture market share in both emerging and mature markets.
This report studies the global Pertussis Vaccine production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Pertussis Vaccine and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Pertussis Vaccine that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Pertussis Vaccine total production and demand, 2021-2032, (M Doses)
Global Pertussis Vaccine total production value, 2021-2032, (USD Million)
Global Pertussis Vaccine production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (M Doses), (based on production site)
Global Pertussis Vaccine consumption by region & country, CAGR, 2021-2032 & (M Doses)
U.S. VS China: Pertussis Vaccine domestic production, consumption, key domestic manufacturers and share
Global Pertussis Vaccine production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (M Doses)
Global Pertussis Vaccine production by Type, production, value, CAGR, 2021-2032, (USD Million) & (M Doses)
Global Pertussis Vaccine production by Application, production, value, CAGR, 2021-2032, (USD Million) & (M Doses)
This report profiles key players in the global Pertussis Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi Pasteur, GSK, Mitsubishi Tanabe Pharma, KM Biologics, Wuhan Institute of Biological Products, Walvax Biotechnology, Chengdu Institute of Biological Products, Minhai Biotechnology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Pertussis Vaccine market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (M Doses) and average price (USD/Doses) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Pertussis Vaccine Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Pertussis Vaccine Market, Segmentation by Type:
DTaP
Tdap
DTwP
Global Pertussis Vaccine Market, Segmentation by Composition:
Acellular Vaccines
Whole-cell Vaccines
Global Pertussis Vaccine Market, Segmentation by User:
Below 12 Months
Above 12 Months
Global Pertussis Vaccine Market, Segmentation by Application:
Hospital
Clinic
Companies Profiled:
Sanofi Pasteur
GSK
Mitsubishi Tanabe Pharma
KM Biologics
Wuhan Institute of Biological Products
Walvax Biotechnology
Chengdu Institute of Biological Products
Minhai Biotechnology
Key Questions Answered:
1. How big is the global Pertussis Vaccine market?
2. What is the demand of the global Pertussis Vaccine market?
3. What is the year over year growth of the global Pertussis Vaccine market?
4. What is the production and production value of the global Pertussis Vaccine market?
5. Who are the key producers in the global Pertussis Vaccine market?
6. What are the growth factors driving the market demand?
In 2024, global Pertussis Vaccine production reached approximately 350 million doses, with an average global market price of around US$ 16 per square meter. Pertussis vaccine is a vaccine that protects against whooping cough. There are two main types: whole-cell vaccines and acellular vaccines. The whole-cell vaccine is about 78% effective while the acellular vaccine is 71–85% effective. In this report, we cover all the pertussis-containing vaccines. Gross margin for the Pertussis vaccine in general shows that manufacturers often achieve roughly 50–70% gross margins, depending on the producer, country, and contract.
The global pertussis vaccine market continues to grow steadily, driven by rising awareness of whooping cough, expanding childhood immunization programs, and increasing recommendations for adolescent and adult Tdap boosters. Demand is especially strong in developing regions where pertussis remains endemic, while mature markets are supported by routine pregnancy immunization and periodic booster campaigns. Major manufacturers focus on improving vaccine safety, supply stability, and combination formulations such as DTaP, which simplify national immunization schedules. Although pricing and procurement are heavily influenced by government tenders and international organizations, overall market growth is supported by public-health initiatives, technological advances in acellular vaccine production, and efforts to increase global vaccination coverage. The pertussis vaccine industrial chain is a complex, highly regulated, and technology-intensive ecosystem that spans from upstream antigen research to downstream global immunization delivery. It is characterized by significant barriers to entry, stringent quality control, and a delicate balance between public health objectives and commercial viability. The chain begins with basic and applied research into Bordetella pertussis antigens. This includes the identification, genetic sequencing, and optimization of key immunogenic components such as Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA), Pertactin (PRN), and Fimbrial proteins (FIM). For acellular vaccines (aP), the upstream segment involves mastering large-scale fermentation, toxin purification, and detoxification (converting PT to Toxoid) processes. This stage also encompasses the production of specialized adjuvants (e.g., aluminum salts) and critical raw materials for cell culture media and buffers. Innovation here focuses on improving antigen yield, purity, stability, and developing novel adjuvant systems to enhance and prolong immunity. The demand for pertussis vaccines is driven by the persistent prevalence of whooping cough, growing awareness of immunization benefits, and expanding vaccination programs for infants, adolescents, and adults. Rising adoption of Tdap boosters during pregnancy and among healthcare workers further fuels market growth. Opportunities exist in developing countries where vaccination coverage is still limited, as well as in urban areas of developed nations with increasing focus on adult immunization and combination vaccines like DTaP to simplify schedules. Additionally, technological innovations in acellular vaccine production, improvements in cold-chain logistics, and government-supported public health initiatives create potential for new market entrants and partnerships. Manufacturers that can offer safe, effective, and easily deployable vaccines, along with reliable supply chains, are well-positioned to capture market share in both emerging and mature markets.
This report studies the global Pertussis Vaccine production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Pertussis Vaccine and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Pertussis Vaccine that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Pertussis Vaccine total production and demand, 2021-2032, (M Doses)
Global Pertussis Vaccine total production value, 2021-2032, (USD Million)
Global Pertussis Vaccine production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (M Doses), (based on production site)
Global Pertussis Vaccine consumption by region & country, CAGR, 2021-2032 & (M Doses)
U.S. VS China: Pertussis Vaccine domestic production, consumption, key domestic manufacturers and share
Global Pertussis Vaccine production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (M Doses)
Global Pertussis Vaccine production by Type, production, value, CAGR, 2021-2032, (USD Million) & (M Doses)
Global Pertussis Vaccine production by Application, production, value, CAGR, 2021-2032, (USD Million) & (M Doses)
This report profiles key players in the global Pertussis Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi Pasteur, GSK, Mitsubishi Tanabe Pharma, KM Biologics, Wuhan Institute of Biological Products, Walvax Biotechnology, Chengdu Institute of Biological Products, Minhai Biotechnology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Pertussis Vaccine market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (M Doses) and average price (USD/Doses) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Pertussis Vaccine Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Pertussis Vaccine Market, Segmentation by Type:
DTaP
Tdap
DTwP
Global Pertussis Vaccine Market, Segmentation by Composition:
Acellular Vaccines
Whole-cell Vaccines
Global Pertussis Vaccine Market, Segmentation by User:
Below 12 Months
Above 12 Months
Global Pertussis Vaccine Market, Segmentation by Application:
Hospital
Clinic
Companies Profiled:
Sanofi Pasteur
GSK
Mitsubishi Tanabe Pharma
KM Biologics
Wuhan Institute of Biological Products
Walvax Biotechnology
Chengdu Institute of Biological Products
Minhai Biotechnology
Key Questions Answered:
1. How big is the global Pertussis Vaccine market?
2. What is the demand of the global Pertussis Vaccine market?
3. What is the year over year growth of the global Pertussis Vaccine market?
4. What is the production and production value of the global Pertussis Vaccine market?
5. Who are the key producers in the global Pertussis Vaccine market?
6. What are the growth factors driving the market demand?
Table of Contents
105 Pages
- 1 Supply Summary
- 2 Demand Summary
- 3 World Manufacturers Competitive Analysis
- 4 United States VS China VS Rest of the World
- 5 Market Analysis by Type
- 6 Market Analysis by Application
- 7 Company Profiles
- 8 Industry Chain Analysis
- 9 Research Findings and Conclusion
- 10 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
